Home/ClearNote Health/Dave Mullarkey
DM

Dave Mullarkey

Chief Executive Officer

ClearNote Health

Therapeutic Areas

ClearNote Health Pipeline

DrugIndicationPhase
Avantect® Pancreatic Cancer TestEarly detection of pancreatic cancerApproved/Commercial
Avantect® Ovarian Cancer TestEarly detection of ovarian cancerApproved/Commercial
Avantect (Pipeline)Lung Cancer Detection (Non-Small Cell Lung Cancer)R&D
Virtuoso PlatformPredictive biomarkers for radioligand therapy (Pancreatic NET)R&D/Collaboration